Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene, Strand Team on HPV Test

NEW YORK (GenomeWeb News) – Trovagene today said that it has entered into a memorandum of understanding with Strand Life Sciences, under which Strand will license and validate Trovagene's human papillomavirus urine test and high-risk HPV DNA assay.

Bangalore, India-based Strand will have rights to offer the test in India and countries in the South Asian Association for Regional Cooperation for clinical diagnostic and carrier screening applications. Strand intends to perform analytical and clinical validation studies on the assay technology in its target markets, with an initial study of the diagnostic accuracy using urine as a specimen in various stages of disease progression.

Strand also intends to validate the clinical utility of HPV DNA testing as a risk indicator and pathological cause of oral cancer in buccal swabs, biopsies, and saliva/sputum specimens.

Further terms of the agreement were not disclosed.

"The potential to use urine, an easily obtained and stable testing sample, for high-risk HPV carrier screening across medically underserved areas is very promising," Vijay Chandru, chairman and CEO of Strand, said in a statement.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.